News

Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials

Dr. George Garibaldi is named Chief Medical Officer as Synendos transitions from Phase 1 into Phase 2 of its clinical development strategy

Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510

Synendos Therapeutics AG announces that co-founder and Scientific Advisor Board member, Professor Jürg Gertsch, presented groundbreaking new findings on an endocannabinoid transporter at the 10th Gordon Research Conference

Synendos Therapeutics is thrilled to announce the formation of the Scientific Advisory Board.

Synendos Series A Extension

Synendos Therapeutics Raises CHF 20 Million in Series A Financing